Home » Stocks » KRBP

Kiromic BioPharma, Inc. (KRBP)

Stock Price: $7.80 USD -0.20 (-2.50%)
Updated May 7, 2021 4:00 PM EDT - Market closed
After-hours: $8.65 +0.85 (10.90%) May 7, 7:11 PM
Market Cap 57.34M
Revenue (ttm) n/a
Net Income (ttm) -19.20M
Shares Out 4.51M
EPS (ttm) -4.42
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 7
Last Price $7.80
Previous Close $8.00
Change ($) -0.20
Change (%) -2.50%
Day's Open 7.75
Day's Range 7.51 - 8.04
Day's Volume 1,746
52-Week Range 7.51 - 18.50

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

HOUSTON--(BUSINESS WIRE)---- $KRBP #KRBP--Kiromic Announces 6 Posters Presented at American Association of Cancer Research 2021 Showcasing our Artificial Intelligence (AI) Biomarker Engine

4 days ago - Business Wire

HOUSTON--(BUSINESS WIRE)---- $KRBP #KRBP--Kiromic BioPharma Reports Fiscal Year 2020 Financial Results and Continued Corporate Progress

1 month ago - Business Wire

HOUSTON--(BUSINESS WIRE)---- $KRBP #KRBP--Kiromic BioPharma, Inc. Interview to Air on Bloomberg Television U.S. on the RedChip Money Report

1 month ago - Business Wire

HOUSTON--(BUSINESS WIRE)--Kiromic Biopharma, Inc. (Nasdaq: KRBP), a target discovery and gene-editing company utilizing artificial intelligence and its proprietary neural network platform with a therape...

1 month ago - Business Wire

HOUSTON--(BUSINESS WIRE)--Kiromic BioPharma, Inc. (Nasdaq: KRBP), an immuno-oncology target discovery and gene-editing company, with a proprietary artificial intelligence neural network platform (Diamon...

3 months ago - Business Wire

HOUSTON--(BUSINESS WIRE)--Kiromic BioPharma, Inc. (Nasdaq: KRBP), an immuno-oncology target discovery and gene-editing company, with a proprietary artificial intelligence neural network platform (Diamon...

3 months ago - Business Wire

HOUSTON--(BUSINESS WIRE)--Kiromic Biopharma, Inc. (Nasdaq: KRBP), a target discovery and gene-editing company utilizing artificial intelligence and proprietary neural network platform with a therapeutic...

4 months ago - Business Wire

HOUSTON--(BUSINESS WIRE)--Kiromic BioPharma (“the Company”) (NASDAQ: KRBP), a target discovery and gene-editing company utilizing artificial intelligence and its proprietary neural network platform with...

4 months ago - Business Wire

HOUSTON--(BUSINESS WIRE)--Kiromic BioPharma (“the Company”) (NASDAQ: KRBP), a pre-clinical stage biotechnology company using its proprietary DIAMOND® artificial intelligence (“A.I.”) platform to improve...

5 months ago - Business Wire

HOUSTON--(BUSINESS WIRE)--Kiromic BioPharma, Inc. (the “Company”), a target discovery and gene-editing company utilizing artificial intelligence and a proprietary neural network platform with a therapeu...

6 months ago - Business Wire

About KRBP

Kiromic BioPharma, Inc., a target discovery and gene editing company, focuses on developing immuno-oncology therapeutics for the treatment of blood cancers and solid tumors. The company develops ALEXIS-ISO-1, an allogenic gamma delta CAR-T cell therapy product candidate targeting Isomesothelin; ALEXIS-PRO-1, an allogeneic gamma delta chimeric T cell therapy product candidate targeting PD-L1; and chimeric gamma delta PD1 T cell switch receptor therapy. It has license agreements with Mercer University; CGA 369 Intellectual Holdings, Inc.; and Lon... [Read more...]

Industry
Biotechnology
IPO Date
Oct 16, 2020
Stock Exchange
NASDAQ
Ticker Symbol
KRBP
Full Company Profile

Financial Performance

Financial Statements